Shares Outstanding (Quarterly) Chart

Historical Shares Outstanding (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
September 30, 2026 4.105M
June 30, 2026 1.949M
March 31, 2026 1.999M
December 31, 2025 0.6464M
September 30, 2025 0.6367M
June 30, 2025 0.5354M
March 31, 2025 10.46M
December 31, 2024 0.4244M
September 30, 2024 6.020M
June 30, 2024 5.904M
March 31, 2024 5.894M
December 31, 2023 5.894M
September 30, 2023 5.885M
June 30, 2023 4.967M
March 31, 2023 4.831M
December 31, 2022 4.830M
September 30, 2022 4.820M
June 30, 2022 4.591M
March 31, 2022 4.582M
December 31, 2021 4.582M
September 30, 2021 4.580M
June 30, 2021 4.580M
March 31, 2021 4.577M
December 31, 2020 4.575M
September 30, 2020 2.833M
Date Value
June 30, 2020 2.532M
March 31, 2020 1.829M
December 31, 2019 1.662M
September 30, 2019 1.660M
June 30, 2019 1.660M
March 31, 2019 1.658M
December 31, 2018 1.658M
September 30, 2018 1.656M
June 30, 2018 1.659M
March 31, 2018 1.656M
December 31, 2017 0.0164M
September 30, 2017 1.640M
June 30, 2017 1.439M
March 31, 2017 1.437M
December 31, 2016 1.411M
September 30, 2016 1.400M
June 30, 2016 1.295M
March 31, 2016 1.290M
December 31, 2015 1.290M
September 30, 2015 1.284M
June 30, 2015 1.284M
March 31, 2015 1.283M
December 31, 2014 0.8603M
September 30, 2014 0.86M
June 30, 2014 0.86M

Shares Outstanding Definition

The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing shares outstanding over time may be the result of company buybacks. Companies frequently make stock buybacks and retire those buybacks as treasury stock.

Read full definition.

Shares Outstanding (Quarterly) Range, Past 5 Years

View Shares Outstanding (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shares Outstanding (Quarterly) Benchmarks

View Shares Outstanding (Quarterly) Benchmarks
Start Trial
Lineage Cell Therapeutics, Inc. 252.91M
Agenus, Inc. 45.21M
Amgen, Inc. 540.90M
Anika Therapeutics, Inc. 13.39M
BioCryst Pharmaceuticals, Inc. 256.12M